March 12, 2020 (Ann Arbor, Michigan)  NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, announced today its plans for a SARS-CoV-2 Assay for use on its high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems.  SARS-CoV-2 is the Coronavirus that has been determined to...

Ann Arbor, MI USA and Milan, Italy (November 25, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on developing testing solutions for hospital and commercial reference laboratory customers, and Sentinel Diagnostics, a leading company engaged in the development and production of diagnostic kits for Clinical Chemistry, Immunochemistry and Molecular Biology, announced today their...

NeuMoDx™ Molecular recently presented the evaluation of DiaSorin Molecular Enterovirus (EV) Primer Pair and Cytomegalovirus (CMV) Primer Pair in Laboratory Developed Test (LDT) Implementation on the open, random-access NeuMoDx™ 288 Molecular System at the Association for Molecular Pathology’s conference held in Baltimore Maryland. Michelle Mastronardi (Director, Systems Integration at NeuMoDx Molecular), along with Stephen Young,...

Ann Arbor, MI (October 16, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today an agreement with Self-screen BV to implement a CE-IVD marked molecular diagnostic test for high-risk strains of human papillomavirus (HPV) on the NeuMoDx™ 288 and NeuMoDx™ 96 Molecular Systems. HPV is the virus regarded...